[SCHEDULE 13G/A] Aligos Therapeutics, Inc. Amended Passive Investment Disclosure
Woodline Reports 4.4% Stake in Aligos Therapeutics
Aligos Therapeutics, Inc. ownership update: Woodline Partners LP reports beneficial ownership of 239,362 shares of Voting Common Stock, representing 4.4% of the class based on 5,387,807 shares outstanding as of March 2, 2026.
Aligos Therapeutics, Inc. ownership update: Woodline Partners LP reports beneficial ownership of 239,362 shares of Voting Common Stock, representing 4.4% of the class based on 5,387,807 shares outstanding as of March 2, 2026. The count includes 62,000 shares issuable upon exercise of warrants.
The filing clarifies sole voting and dispositive power over the reported shares and is presented by Woodline as investment adviser to Woodline Master Fund LP. The statement is an ownership disclosure amendment and does not itself effect any transaction.
Positive
None.
Negative
None.
Insights
Woodline reports a sub-5% stake including warrant exposure.
Woodline Partners discloses 239,362 shares beneficially owned and notes 62,000 shares issuable upon warrant exercise. The ownership percentage is calculated on March 2, 2026 using 5,387,807 shares outstanding.
Because the position is under 5%, it is a routine Schedule 13G/A disclosure; subsequent filings would show any material changes in voting or disposition power.
Amendment clarifies beneficial ownership and power attribution.
The filing states Woodline Partners acts as investment adviser to the Woodline Fund and reports sole voting and dispositive power over the reported shares. It reiterates customary Section 13 ownership caveats and provides an as-of anchor for the outstanding share base.
Compliance teams should note the warrant inclusion in the ownership calculation and track any exercises or threshold-crossing events for future reporting obligations.
Key Figures
Beneficially owned shares:239,362 sharesPercent of class:4.4%Outstanding shares used:5,387,807 shares+1 more
4 metrics
Beneficially owned shares239,362 sharesreported by Woodline Partners
Percent of class4.4%calculated on 5,387,807 shares outstanding as of March 2, 2026
Outstanding shares used5,387,807 sharesshares outstanding as of March 2, 2026
Warrants included62,000 sharesissuable upon exercise of warrants, included in ownership count
"This statement is filed by Woodline Partners LP ("Woodline Partners" or the"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficial ownershipregulatory
"Amount beneficially owned: The information required by Item 4(a) is set forth"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
dispositive powerregulatory
"Sole Dispositive Power 239,362.00"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
warrantsfinancial
"Includes 62,000 shares of Voting Common Stock issuable upon exercise of warrants."
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Woodline Partners report in ALGS?
Woodline Partners reports beneficial ownership of 239,362 shares, equal to 4.4% of the class based on 5,387,807 shares outstanding as of March 2, 2026. The reported count includes 62,000 shares issuable upon warrant exercise.
Does the 4.4% calculation include warrants in ALGS?
Yes. The 4.4% figure assumes exercise of warrants and explicitly states the ownership count includes 62,000 shares issuable upon exercise of warrants, per the filing's cover-page comment and Item 4 disclosure.
Who holds voting and dispositive power for the reported ALGS shares?
The filing states Woodline Partners has sole voting power and sole dispositive power over the 239,362 shares reported. It identifies Woodline as investment adviser to the Woodline Master Fund LP, the direct holder of the shares.
What share count and date were used to calculate the percentage for ALGS?
The percentage is calculated using an aggregate of 5,387,807 shares outstanding as of March 2, 2026, according to the company’s Annual Report on Form 10-K filed March 5, 2026, which the amendment references for the outstanding share base.
Does this Schedule 13G/A indicate a change in holdings for ALGS?
This amendment updates prior reporting to clarify ownership details and the inclusion of warrant-issuable shares. It reports the 239,362-share position and power attribution; it does not state an executed buy or sell transaction in this filing.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
Aligos Therapeutics, Inc.
(Name of Issuer)
Voting Common Stock, par value $0.0001 per share
(Title of Class of Securities)
01626L204
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
01626L204
1
Names of Reporting Persons
Woodline Partners LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
239,362.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
239,362.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
239,362.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.4 %
12
Type of Reporting Person (See Instructions)
PN, IN
Comment for Type of Reporting Person: Includes 62,000 shares of Voting Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Aligos Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
One Corporate Drive, 2nd Flood, South San Francisco, CA 94080
Item 2.
(a)
Name of person filing:
This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of voting common stock, par value $0.0001 per share ("Voting Common Stock"), and shares of Voting Common Stock issuable upon exercise of warrants of Aligos Therapeutics, Inc. (the "Company") directly held by the Woodline Fund.
The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Voting Common Stock reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)
Citizenship:
Woodline Partners is a Delaware limited partnership.
(d)
Title of class of securities:
Voting Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
01626L204
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 5,387,807 shares of Voting Common Stock outstanding as of March 2, 2026, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 5, 2026, and assumes the exercise of the warrants reported herein.
(b)
Percent of class:
4.4%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Woodline Partners LP
Signature:
/s/ Erin Mullen
Name/Title:
Erin Mullen, General Counsel & Chief Compliance Officer
